BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1438449)

  • 1. Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
    Min WS; Park HM; Han CH; Park JW; Kim CC; Kim DJ
    Prog Clin Biol Res; 1992; 377():87-95. PubMed ID: 1438449
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro effects of Ilmofosine on acute lymphoblastic leukemia cells and on normal hemopoietic cells.
    Skala JP; Rogers PC; Chan KW; Khangura SS; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():63-9. PubMed ID: 1438445
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP; Rogers PC; Chan KW; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow purging with antisense oligodeoxynucleotides.
    Gewirtz AM
    Prog Clin Biol Res; 1992; 377():215-24; discussion 225-6. PubMed ID: 1438418
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroblastoma purging by immunorosette depletion.
    Slaper-Cortenbach IC; de Vries-van Rossen A; Huijbens RJ; van Leeuwen EF; Figdor CG
    Prog Clin Biol Res; 1992; 377():147-62. PubMed ID: 1438411
    [No Abstract]   [Full Text] [Related]  

  • 7. Purging of acute lymphoblastic leukemia by long-term marrow culture.
    Douay L; Ozsahin H; Barbu V; Fabrega S; Giarratana MC; Da WM; Allieri A; Gorin NC
    Prog Clin Biol Res; 1992; 377():205-13; discussion 214. PubMed ID: 1438417
    [No Abstract]   [Full Text] [Related]  

  • 8. Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma.
    Skala JP; Rogers PC; Chan KW; Chao HY; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():71-8. PubMed ID: 1438447
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
    Kramer B; Makrynikola V; Bradstock K
    Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
    [No Abstract]   [Full Text] [Related]  

  • 10. The cytotoxicity of alkyl-lysophospholipid on clonogenic leukemia cells and on normal bone marrow progenitor cells is highly, but differentially, increased by cryopreservation.
    Verdonck LF; Heesbeen EC; van Heugten HG; Staal GE; Rijksen G
    Bone Marrow Transplant; 1992 Apr; 9(4):241-5. PubMed ID: 1600412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory activity of endogenous MIP-1 alpha in long-term cultures of human marrow.
    Cashman JD; Eaves AC; Wolpe S; Eaves CJ
    Prog Clin Biol Res; 1994; 389():261-8. PubMed ID: 7700910
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
    Makrynikola V; Kabral A; Bradstock KF
    Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purging with 4-hydroperoxycyclophosphamide combinations.
    Jones RJ; Miller CB; Rowley SD
    Prog Clin Biol Res; 1992; 377():1-9; discussion 10-1. PubMed ID: 1438406
    [No Abstract]   [Full Text] [Related]  

  • 14. Alkyl-lysophospholipid purging for autologous bone marrow transplantation in acute leukemia in second or subsequent remission after extramedullary relapse.
    Berdel WE; Vogler WR; Olson AC
    Prog Clin Biol Res; 1992; 377():79-85. PubMed ID: 1438448
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
    Gidáli J; Fehér I; Kovács P
    Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R; Bony V; Lopez M
    Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone marrow purging in patients with refractory cancer.
    Meagher RC; Stevens DA; Herzig GP; Fay JW; Harden EA; Montes VM; Heye MM; Herzig RH
    Prog Clin Biol Res; 1992; 377():281-7. PubMed ID: 1438426
    [No Abstract]   [Full Text] [Related]  

  • 19. Importance of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts.
    Sieber F; Gaffney DK; Yamazaki T; Qiu K
    Prog Clin Biol Res; 1994; 389():147-54. PubMed ID: 7700897
    [No Abstract]   [Full Text] [Related]  

  • 20. [Role of marrow purging].
    Rizzoli V; Carlo-Stella C; Mangoni L
    Haematologica; 1991 Jun; 76 Suppl 3():311-20. PubMed ID: 1684346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.